BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35088050)

  • 1. GammaTile® brachytherapy in the treatment of recurrent glioblastomas.
    Gessler DJ; Neil EC; Shah R; Levine J; Shanks J; Wilke C; Reynolds M; Zhang S; Özütemiz C; Gencturk M; Folkertsma M; Bell WR; Chen L; Ferreira C; Dusenbery K; Chen CC
    Neurooncol Adv; 2022; 4(1):vdab185. PubMed ID: 35088050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GammaTile
    Yekula A; Gessler DJ; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
    J Neurooncol; 2024 Feb; 166(3):441-450. PubMed ID: 38281303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GammaTile® (GT) as a brachytherapy platform for rapidly growing brain metastasis.
    Dharnipragada R; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
    Neurooncol Adv; 2023; 5(1):vdad062. PubMed ID: 37324216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GammaTile Brachytherapy Combined With External Beam Radiation Therapy for the Treatment of a Partially Resected Secondary Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching External Beam Dose Gradient to Brachytherapy Dose Fall-Off.
    Peach MS; Burke AM; Jo J; Ju AW; Yang K
    Cureus; 2021 Nov; 13(11):e19717. PubMed ID: 34934580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
    Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
    World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Outcomes of Novel Collagen Tile Cesium Brachytherapy for Recurrent Intracranial Tumors at a Tertiary Referral Center.
    Warren KT; Boucher A; Bray DP; Dresser S; Zhong J; Shu HK; Olson J; Hoang K
    Cureus; 2021 Nov; 13(11):e19777. PubMed ID: 34950555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection and Surgically Targeted Radiation Therapy for the Treatment of Larger Recurrent or Newly Diagnosed Brain Metastasis: Results From a Prospective Trial.
    Nakaji P; Smith K; Youssef E; Thomas T; Pinnaduwage D; Rogers L; Wallstrom G; Brachman D
    Cureus; 2020 Nov; 12(11):e11570. PubMed ID: 33224684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GammaTile for Gliomas: A Single-Center Case Series.
    Budnick HC; Richardson AM; Shiue K; Watson G; Ng SK; Le Y; Shah MV
    Cureus; 2021 Nov; 13(11):e19390. PubMed ID: 34925992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
    Bunevicius A; Pikis S; Kondziolka D; Patel DN; Bernstein K; Sulman EP; Lee CC; Yang HC; Delabar V; Mathieu D; Cifarelli CP; Arsanious DE; Dahshan BA; Weir JS; Speckter H; Mota A; Tripathi M; Kumar N; Warnick RE; Peker S; Samanci Y; Barnett G; Hefnawi FE; Al Sideiri G; Sheehan J
    J Neurooncol; 2021 Dec; 155(3):343-351. PubMed ID: 34797526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
    Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
    J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.